Conflict of interest
Nordisk, Craniopharyngioma
CRANIOPHARYNGIOMA
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.Prof. HM, Dr. CD, and Dr. HvS have received travel and accommodation costs for an international meeting from Rhythm Pharmaceuticals. The Princess Máxima Center has received funding for the organization of the 6th Post-graduate course Craniopharyngioma in 2023 from the companies Rhythm Pharmaceuticals, Novo Nordisk and Pfizer.The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.